Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment
Background Cyclosporin induces a dramatic reversal to normality in psoriatic lesions, with a reduction of inflammatory infiltrate and epidermal proliferation. It is known that the cell cycle and cell proliferation are regulated by the sequential activation of cyclin‐dependent kinase/cyclin complexes...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2000-11, Vol.143 (5), p.950-956 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 956 |
|---|---|
| container_issue | 5 |
| container_start_page | 950 |
| container_title | British journal of dermatology (1951) |
| container_volume | 143 |
| creator | Miracco, C. Pellegrino, M. Flori, M.L. Vatti, R. Materno, M. Andreassi, L. |
| description | Background Cyclosporin induces a dramatic reversal to normality in psoriatic lesions, with a reduction of inflammatory infiltrate and epidermal proliferation. It is known that the cell cycle and cell proliferation are regulated by the sequential activation of cyclin‐dependent kinase/cyclin complexes.
Aim We evaluated epidermal cell turnover and thickness, as well as the expression of cyclins D1, B and A in psoriatic skin before and after therapy with cyclosporin.
Methods Epidermal thickness, mitotic and apoptotic indices (MI, AI), as well as the percentages of epidermal cell nuclei positive for Ki‐67 and cyclins D1, B and A were calculated. Cytoplasmic positivity to cyclin B was also evaluated.
Results After 6 weeks of therapy, we observed a clinical improvement of the disease and normalization of the epidermis. Epidermal thickness and Ki‐67‐, cyclins B‐ and A‐positive nuclei percentage were significantly higher before therapy than after (0·52 ± 0·05 mm vs. 0·21 ± 0·03 mm, P |
| doi_str_mv | 10.1046/j.1365-2133.2000.03826.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72405881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>64860181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5246-1faf52f311d553da90f1cbe74905e9d0a8e29bfe6d3adb6f70042dc7d6c4e3d93</originalsourceid><addsrcrecordid>eNqNkUtv1DAQgC0EotvCX0AWSJyaMI5jJzlwaLcPQKVIFajcLMceS9lmk9TO0t1_X2d3tUicOPkx3zf2zBBCGaQMcvlpkTIuRZIxztMMAFLgZSbT9QsyOwReklmMFAlUkh-R4xAWAIyDgNfkiDGQlQA2I8N8Y9qmoxfslJ5T3Vl6RnE9eAyh6bvthcG2pePKd_0f9DSyQ-h9o8fG0PAQjy1OaKA1ut7jVtFujKiJqfswRLijo0c9LrEb35BXTrcB3-7XE_Lr6vLn_Ety8-P66_zsJjEiy2XCnHYic5wxKwS3ugLHTI1FXoHAyoIuMatqh9JybWvpCoA8s6aw0uTIbcVPyMdd3sH3jysMo1o2YSpFd9ivgiqyHERZsgi-_wdc9LHY-Dc1tVayvCwjVO4g4_sQPDo1-Gap_UYxUNNI1EJNnVdT57ee2o5EraP6bp9_VS_R_hX3M4jAhz2gg9Gt87ozTThwJUheTNTnHfXUtLj57-fV-beLaRf9ZOc3YcT1wdf-QcmCF0Ld316r7Pf9XX73_VZJ_gwc3bYJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200061488</pqid></control><display><type>article</type><title>Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Miracco, C. ; Pellegrino, M. ; Flori, M.L. ; Vatti, R. ; Materno, M. ; Andreassi, L.</creator><creatorcontrib>Miracco, C. ; Pellegrino, M. ; Flori, M.L. ; Vatti, R. ; Materno, M. ; Andreassi, L.</creatorcontrib><description>Background Cyclosporin induces a dramatic reversal to normality in psoriatic lesions, with a reduction of inflammatory infiltrate and epidermal proliferation. It is known that the cell cycle and cell proliferation are regulated by the sequential activation of cyclin‐dependent kinase/cyclin complexes.
Aim We evaluated epidermal cell turnover and thickness, as well as the expression of cyclins D1, B and A in psoriatic skin before and after therapy with cyclosporin.
Methods Epidermal thickness, mitotic and apoptotic indices (MI, AI), as well as the percentages of epidermal cell nuclei positive for Ki‐67 and cyclins D1, B and A were calculated. Cytoplasmic positivity to cyclin B was also evaluated.
Results After 6 weeks of therapy, we observed a clinical improvement of the disease and normalization of the epidermis. Epidermal thickness and Ki‐67‐, cyclins B‐ and A‐positive nuclei percentage were significantly higher before therapy than after (0·52 ± 0·05 mm vs. 0·21 ± 0·03 mm, P < 0·001; 19 vs. 2·6, 19 vs. 3, and 12 vs. 1, respectively; P < 0·0005); cytoplasmic positivity to cyclin B was slightly higher before therapy (score 3 vs. 2–3). Cyclin D1 was negative or expressed in a low percentage of nuclei in psoriasis before therapy (0·78), whereas it was always negative after therapy. MI was 0·15 before therapy, whereas mitoses were almost absent afterwards. Apoptoses were undetectable before therapy, whereas a few apoptoses were observed after treatment (AI = 0·4).
Conclusions Overexpression of cyclins B and A, rather than D1 seems to characterize psoriasis. Their evaluation could provide further insights in understanding the development of this disorder and could be used to verify the efficacy of currently used therapies as well as future ones.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1046/j.1365-2133.2000.03826.x</identifier><identifier>PMID: 11069501</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Biological and medical sciences ; Biomarkers - analysis ; Cell Division - drug effects ; Cyclin A - metabolism ; Cyclin B - metabolism ; Cyclin D1 - metabolism ; cyclins ; Cyclins - metabolism ; Cyclosporine - therapeutic use ; Dermatologic Agents - therapeutic use ; Dermatology ; Epidermis - metabolism ; Epidermis - pathology ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; psoriasis ; Psoriasis - drug therapy ; Psoriasis - metabolism ; Psoriasis - pathology ; Psoriasis. Parapsoriasis. Lichen ; Skin, nail, hair, dermoskeleton ; therapy</subject><ispartof>British journal of dermatology (1951), 2000-11, Vol.143 (5), p.950-956</ispartof><rights>British Association of Dermatologists, 2000</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Nov 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5246-1faf52f311d553da90f1cbe74905e9d0a8e29bfe6d3adb6f70042dc7d6c4e3d93</citedby><cites>FETCH-LOGICAL-c5246-1faf52f311d553da90f1cbe74905e9d0a8e29bfe6d3adb6f70042dc7d6c4e3d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2133.2000.03826.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2133.2000.03826.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=806371$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11069501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miracco, C.</creatorcontrib><creatorcontrib>Pellegrino, M.</creatorcontrib><creatorcontrib>Flori, M.L.</creatorcontrib><creatorcontrib>Vatti, R.</creatorcontrib><creatorcontrib>Materno, M.</creatorcontrib><creatorcontrib>Andreassi, L.</creatorcontrib><title>Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Background Cyclosporin induces a dramatic reversal to normality in psoriatic lesions, with a reduction of inflammatory infiltrate and epidermal proliferation. It is known that the cell cycle and cell proliferation are regulated by the sequential activation of cyclin‐dependent kinase/cyclin complexes.
Aim We evaluated epidermal cell turnover and thickness, as well as the expression of cyclins D1, B and A in psoriatic skin before and after therapy with cyclosporin.
Methods Epidermal thickness, mitotic and apoptotic indices (MI, AI), as well as the percentages of epidermal cell nuclei positive for Ki‐67 and cyclins D1, B and A were calculated. Cytoplasmic positivity to cyclin B was also evaluated.
Results After 6 weeks of therapy, we observed a clinical improvement of the disease and normalization of the epidermis. Epidermal thickness and Ki‐67‐, cyclins B‐ and A‐positive nuclei percentage were significantly higher before therapy than after (0·52 ± 0·05 mm vs. 0·21 ± 0·03 mm, P < 0·001; 19 vs. 2·6, 19 vs. 3, and 12 vs. 1, respectively; P < 0·0005); cytoplasmic positivity to cyclin B was slightly higher before therapy (score 3 vs. 2–3). Cyclin D1 was negative or expressed in a low percentage of nuclei in psoriasis before therapy (0·78), whereas it was always negative after therapy. MI was 0·15 before therapy, whereas mitoses were almost absent afterwards. Apoptoses were undetectable before therapy, whereas a few apoptoses were observed after treatment (AI = 0·4).
Conclusions Overexpression of cyclins B and A, rather than D1 seems to characterize psoriasis. Their evaluation could provide further insights in understanding the development of this disorder and could be used to verify the efficacy of currently used therapies as well as future ones.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>Cell Division - drug effects</subject><subject>Cyclin A - metabolism</subject><subject>Cyclin B - metabolism</subject><subject>Cyclin D1 - metabolism</subject><subject>cyclins</subject><subject>Cyclins - metabolism</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Dermatology</subject><subject>Epidermis - metabolism</subject><subject>Epidermis - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - metabolism</subject><subject>Psoriasis - pathology</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>therapy</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAQgC0EotvCX0AWSJyaMI5jJzlwaLcPQKVIFajcLMceS9lmk9TO0t1_X2d3tUicOPkx3zf2zBBCGaQMcvlpkTIuRZIxztMMAFLgZSbT9QsyOwReklmMFAlUkh-R4xAWAIyDgNfkiDGQlQA2I8N8Y9qmoxfslJ5T3Vl6RnE9eAyh6bvthcG2pePKd_0f9DSyQ-h9o8fG0PAQjy1OaKA1ut7jVtFujKiJqfswRLijo0c9LrEb35BXTrcB3-7XE_Lr6vLn_Ety8-P66_zsJjEiy2XCnHYic5wxKwS3ugLHTI1FXoHAyoIuMatqh9JybWvpCoA8s6aw0uTIbcVPyMdd3sH3jysMo1o2YSpFd9ivgiqyHERZsgi-_wdc9LHY-Dc1tVayvCwjVO4g4_sQPDo1-Gap_UYxUNNI1EJNnVdT57ee2o5EraP6bp9_VS_R_hX3M4jAhz2gg9Gt87ozTThwJUheTNTnHfXUtLj57-fV-beLaRf9ZOc3YcT1wdf-QcmCF0Ld316r7Pf9XX73_VZJ_gwc3bYJ</recordid><startdate>200011</startdate><enddate>200011</enddate><creator>Miracco, C.</creator><creator>Pellegrino, M.</creator><creator>Flori, M.L.</creator><creator>Vatti, R.</creator><creator>Materno, M.</creator><creator>Andreassi, L.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>200011</creationdate><title>Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment</title><author>Miracco, C. ; Pellegrino, M. ; Flori, M.L. ; Vatti, R. ; Materno, M. ; Andreassi, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5246-1faf52f311d553da90f1cbe74905e9d0a8e29bfe6d3adb6f70042dc7d6c4e3d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>Cell Division - drug effects</topic><topic>Cyclin A - metabolism</topic><topic>Cyclin B - metabolism</topic><topic>Cyclin D1 - metabolism</topic><topic>cyclins</topic><topic>Cyclins - metabolism</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Dermatology</topic><topic>Epidermis - metabolism</topic><topic>Epidermis - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - metabolism</topic><topic>Psoriasis - pathology</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miracco, C.</creatorcontrib><creatorcontrib>Pellegrino, M.</creatorcontrib><creatorcontrib>Flori, M.L.</creatorcontrib><creatorcontrib>Vatti, R.</creatorcontrib><creatorcontrib>Materno, M.</creatorcontrib><creatorcontrib>Andreassi, L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miracco, C.</au><au>Pellegrino, M.</au><au>Flori, M.L.</au><au>Vatti, R.</au><au>Materno, M.</au><au>Andreassi, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2000-11</date><risdate>2000</risdate><volume>143</volume><issue>5</issue><spage>950</spage><epage>956</epage><pages>950-956</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>Background Cyclosporin induces a dramatic reversal to normality in psoriatic lesions, with a reduction of inflammatory infiltrate and epidermal proliferation. It is known that the cell cycle and cell proliferation are regulated by the sequential activation of cyclin‐dependent kinase/cyclin complexes.
Aim We evaluated epidermal cell turnover and thickness, as well as the expression of cyclins D1, B and A in psoriatic skin before and after therapy with cyclosporin.
Methods Epidermal thickness, mitotic and apoptotic indices (MI, AI), as well as the percentages of epidermal cell nuclei positive for Ki‐67 and cyclins D1, B and A were calculated. Cytoplasmic positivity to cyclin B was also evaluated.
Results After 6 weeks of therapy, we observed a clinical improvement of the disease and normalization of the epidermis. Epidermal thickness and Ki‐67‐, cyclins B‐ and A‐positive nuclei percentage were significantly higher before therapy than after (0·52 ± 0·05 mm vs. 0·21 ± 0·03 mm, P < 0·001; 19 vs. 2·6, 19 vs. 3, and 12 vs. 1, respectively; P < 0·0005); cytoplasmic positivity to cyclin B was slightly higher before therapy (score 3 vs. 2–3). Cyclin D1 was negative or expressed in a low percentage of nuclei in psoriasis before therapy (0·78), whereas it was always negative after therapy. MI was 0·15 before therapy, whereas mitoses were almost absent afterwards. Apoptoses were undetectable before therapy, whereas a few apoptoses were observed after treatment (AI = 0·4).
Conclusions Overexpression of cyclins B and A, rather than D1 seems to characterize psoriasis. Their evaluation could provide further insights in understanding the development of this disorder and could be used to verify the efficacy of currently used therapies as well as future ones.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11069501</pmid><doi>10.1046/j.1365-2133.2000.03826.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2000-11, Vol.143 (5), p.950-956 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72405881 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Biological and medical sciences Biomarkers - analysis Cell Division - drug effects Cyclin A - metabolism Cyclin B - metabolism Cyclin D1 - metabolism cyclins Cyclins - metabolism Cyclosporine - therapeutic use Dermatologic Agents - therapeutic use Dermatology Epidermis - metabolism Epidermis - pathology Female Follow-Up Studies Humans Immunosuppressive Agents - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments psoriasis Psoriasis - drug therapy Psoriasis - metabolism Psoriasis - pathology Psoriasis. Parapsoriasis. Lichen Skin, nail, hair, dermoskeleton therapy |
| title | Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cyclin%20D1,%20B%20and%20A%20expression%20and%20cell%20turnover%20in%20psoriatic%20skin%20lesions%20before%20and%20after%20cyclosporin%20treatment&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Miracco,%20C.&rft.date=2000-11&rft.volume=143&rft.issue=5&rft.spage=950&rft.epage=956&rft.pages=950-956&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1046/j.1365-2133.2000.03826.x&rft_dat=%3Cproquest_cross%3E64860181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200061488&rft_id=info:pmid/11069501&rfr_iscdi=true |